MyChesCo on MSN4d
Mineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Treating Sleep Apnea and Hypertension
RADNOR, PA — Mineralys Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its ...
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials
An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available. Mineralys Therapeutics announced that the U.S. FDA ...
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions ...
ETF Daily News15d
Mineralys Therapeutics (NASDAQ:MLYS) Trading Up 4% – Here’s Why
Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) shot up 4% during trading on Friday .The stock traded as high as $13.43 and last traded at $13.39. 9,138 shares were traded ...
Pharmabiz3d
Mineralys Therapeutics gets US FDA nod to begin phase 2 trial of lorundrostat for OSA in patients with hypertension
Radnor, Pennsylvania Friday, January 10, 2025, 18:00 Hrs [IST] ...
Mineralys announces Phase 2 trial of lorundrostat in OSA
Mineralys Therapeutics (MLYS) announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug (IND) ...
Yahoo Finance5d
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
RADNOR, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension ...